<DOC>
<DOCNO>EP-0623615</DOCNO> 
<TEXT>
<INVENTION-TITLE>
Substituted 1-phenyl-oxazolidin-2-one derivatives, their preparation and their use as adhesion-receptor antagonists
</INVENTION-TITLE>
<CLASSIFICATIONS>C07D26320	A61K31445	A61P908	C07D41306	C07D26300	A61P1910	A61K31421	A61P4300	C07D41906	C07D41300	A61K314427	A61K31495	A61K31496	C07D49100	A61P900	C07D491107	A61K31496	A61K31425	A61K31421	A61P700	A61K31422	A61P3500	C07D40306	A61K3142	C07D40106	C07D40100	C07D27714	A61K31426	C07D23300	C07D23336	C07D26300	A61P900	C07D29500	A61K31426	C07D49800	C07D40300	A61K31415	A61K3155	C07D49110	A61K314427	C07D29500	C07D41900	A61P1900	C07D49810	A61K31425	A61K31415	A61K31445	A61P2900	C07D27700	A61K3155	A61P3500	A61P910	A61P702	A61K314166	A61K31495	A61P2900	A61K31422	A61P4300	A61K314164	A61K3142	</CLASSIFICATIONS>
<CLASSIFICATIONS-THIRD>C07D	A61K	A61P	C07D	C07D	A61P	A61K	A61P	C07D	C07D	A61K	A61K	A61K	C07D	A61P	C07D	A61K	A61K	A61K	A61P	A61K	A61P	C07D	A61K	C07D	C07D	C07D	A61K	C07D	C07D	C07D	A61P	C07D	A61K	C07D	C07D	A61K	A61K	C07D	A61K	C07D	C07D	A61P	C07D	A61K	A61K	A61K	A61P	C07D	A61K	A61P	A61P	A61P	A61K	A61K	A61P	A61K	A61P	A61K	A61K	</CLASSIFICATIONS-THIRD>
<CLASSIFICATIONS-FOURTH>C07D263	A61K31	A61P9	C07D413	C07D263	A61P19	A61K31	A61P43	C07D419	C07D413	A61K31	A61K31	A61K31	C07D491	A61P9	C07D491	A61K31	A61K31	A61K31	A61P7	A61K31	A61P35	C07D403	A61K31	C07D401	C07D401	C07D277	A61K31	C07D233	C07D233	C07D263	A61P9	C07D295	A61K31	C07D498	C07D403	A61K31	A61K31	C07D491	A61K31	C07D295	C07D419	A61P19	C07D498	A61K31	A61K31	A61K31	A61P29	C07D277	A61K31	A61P35	A61P9	A61P7	A61K31	A61K31	A61P29	A61K31	A61P43	A61K31	A61K31	</CLASSIFICATIONS-FOURTH>
<ABSTRACT>
Novel compounds of the formula I 
<
IMAGE
>
  in which R
<
1
>
, X and Y have the meanings given in Patent Claim 1, and their salts inhibit the binding of fibrinogen to the fibrinogen receptor and can be used for the treatment of thromboses, apoplexy, cardiac infarcts, inflammations, arteriosclerosis, osteoporosis and tumours.
</ABSTRACT>
<APPLICANTS>
</APPLICANTS>
<INVENTORS>
</INVENTORS>
<CLAIMS>
Compounds of the formula I


in which

X
is O,
Y
is an aziridino, azetidino, pyrrolidino, piperidino,
1-oxa-8-azaspiro[4.5]
dec-9-yl, hexahydroazepino or
4-R
4
-piperazino radical which is unsubstituted or
substituted once by R
2
, which can additionally be
substituted by an OZ, SZ or N(Z)
2
 group and/or by
carbonyl oxygen,
Z
is in each case H, A, phenyl-C
k
H
2k
 or acyl having 1-11
C atoms,
R
1
is a phenyl radical which is substituted once by CN,
H
2
N-CH
2
-, (A)
2
N-CH
2
-, H
2
N-C(=NH)-, H
2
N-C(=NH)-NH-,
H
2
N-C(=NH)-NH-CH
2
-, HO-NH-C(=NH)- or HO-NH-C(=NH)-NH,
R
2
is -C
m
H
2m
-COOR
3
 or -C
n
H
2n
-O-C
p
H
2p
-COOR
3
,
R
3
is H, A or benzyl,
R
4
is H, A, benzyl or -C
m
H
2m
-COOR
3
,
A
is in each case alkyl having 1-6 C atoms,
k
and m are in each case 0, 1, 2 or 3,
n
is 0, 1 or 2, and
p
is 1, 2 or 3,

and salts thereof.
1-(3-(4-Amidinophenyl)-2-oxo-5-oxazolidinylmethyl)piperidine-4-carboxylic
acid according to Claim 1. 
Process for preparing a compound of the formula
I according to Patent Claim 1, and its salts, characterized

in that

(a) a compound of the formula I is liberated from one of
its functional derivatives by treating with a solvolysing

or hydrogenolysing agent, or in that
(b) a compound of the formula II


in which

E is Cl, Br, I, or a reactive esterified OH group,
and
R
1
 and X have the meanings given in Claim 1,

is reacted with an amino compound of the formula III

H-Y

in which

Y has the meaning given in Claim 1,

or in that
(c) a compound of the formula IV


R
1
-NH-CH
2
-CH(XH)-CH
2
-Y

in which

R
1
, X and Y have the meanings given in Claim 1, or
one of its reactive derivatives,

is reacted with a reactive derivative of carbonic
acid, or in that
(d) in order to prepare a guanidino compound of the
formula I (R
1
 = phenyl radical substituted once by
H
2
N-C(=NH)-NH), an amino compound corresponding to
the formula I, which, however, contains an aminophenyl

group in place of the radical R
1
, is treated 
with an amidinating agent,

and/or in that, in a compound of the formula I, one or
both radicals R
1
 and/or Y is/are transformed into
(an)other radical(s) R
1
 and/or Y, and/or a compound of
the formula I is converted into one of its salts by

treatment with an acid or a base.
Process for preparing pharmaceutical formulations,
characterized in that a compound of the formula I

according to Claim 1 and/or one of its physiologically
harmless salts is/are brought into a suitable dosage form

together with at least one solid, liquid or semi-liquid
excipient or auxiliary agent.
Pharmaceutical formulation, characterized by a
content of at least one compound of the formula I

according to Claim 1 and/or one of its physiologically
harmless salts.
Use of compounds of the formula I according to
Claim 1, or of their physiologically harmless salts, for

preparing a medicament.
Use of compounds of the formula I according to
Claim 1, or of their physiologically harmless salts, in

the control of thromboses, cardiac infarctions, stroke,
osteoporosis, arteriosclerosis, inflammations and/or

tumours.
</CLAIMS>
</TEXT>
</DOC>
